Javle et al. [80], in a multicentric open-label phase II study, evaluated the use of Pertuzumab and Trastuzumab for Her2-positive stage IV cholangiocarcinoma (MyPathway). This evidence concerns the gene ERBB2 and cholangiocarcinoma.